Current Research Studies

Cancer – NANT-2013-01: Immunotherapy of relapsed refractory neuroblastoma with Expanded NK Cells, Dinutuximab and Lenalidomide

Condition or Therapy:



Cancer and blood disorders

What is the goal of this study?

The goal of this study is to assess the maximum tolerated dose of autologous expanded natural killer (NK) cells that can be combined with ch14.18 (drug) and how much lenalidomide can be added at the recommended level.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are 1 month to 30 years old and
  • Have been diagnosed with neuroblastoma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Navin Pinto